Status: Recruiting
Study to Evaluate the Efficacy and Safety of DW1807 in Perennial Allergic Rhinitis Patients With Asthma
This study aims to compare the efficacy and safety of DW1807 and DW1807-R2 in patients with perennial allergic rhinitis and comorbid asthma. The primary objective is to demonstrate the superiority of DW1807 over DW1807-R2 in improving the reflective total nasal symptom score (rTNSS) after 4 weeks of treatment.
Participants needed: 274
Trial details
Phase: Phase 3Age: 19+Biological sex: AllType: InterventionalSponsor: Daewon Pharmaceutical Co., Ltd.Updated: Sep 11, 2025Locations: 1
Eligibility criteria
Male or female adults aged 19 years or older. [+6]
Individuals diagnosed with non-allergic rhinitis of other causes. [+10]